Abstract:Ovarian cancer is a deadly female cancer with high rates of recurrence. The primary treatment strategy for patients is platinum-based therapy regimens that almost universally develop resistance. Consequently, new therapeutic avenues are needed to overcome the plateau that current therapies have on patient outcomes. We describe a gene amplification involving both HSF1 and MYC, wherein these two genes on chromosome 8q are co-amplified in over 7% of human tumors that is enriched to over 30% of patients with ovarian cancer. We further found that HSF1 and MYC transcriptional activity is correlated in human tumors and ovarian cancer cell lines, suggesting they may cooperate in ovarian cancer cells. CUT&RUN for HSF1 and MYC in co-amplified ovarian cancer cells revealed that HSF1 and MYC have overlapping binding at a substantial number of locations throughout the genome where their binding peaks are near identical. Consistent with these data, a protein-protein interaction between HSF1 and MYC was detected in ovarian cancer cells, implying these two transcription factors have a molecular cooperation. Further supporting their cooperation, growth of HSF1-MYC co-amplified ovarian cancer cells were found to be dependent on both HSF1 and MYC. In an attempt to identify a therapeutic target that could take advantage of this dependency on both HSF1 and MYC, PLK1 was identified as being correlated with HSF1 and MYC in primary human tumor specimens, consistent with a previously established effect of PLK1 on HSF1 and MYC protein levels. Targeting PLK1 with the compound volasertib (BI-6727) revealed a greater than 200-fold increased potency of volasertib in HSF1-MYC co-amplified ovarian cancer cells compared to ovarian cancer cells wild-type HSF1 and MYC copy number, which extended to several growth assays, including spheroid growth. Volasertib, and other PLK1 inhibitors, have not shown great success in clinical trials and this study suggests that targeting PLK1 may be viable in a precision medicine approach using HSF1-MYC co-amplification as a biomarker for response.

The Polyoma Virus Large T Binding Protein P150 is a Transcriptional Repressor of C-Myc

Solute Carrier Family 27 Member 6 (SLC27A6) Possibly Promotes the Proliferation of Papillary Thyroid Cancer by Regulating c-MYC

HCMV IE2-mediated Inhibition of HAT Activity Downregulates P53 Function

The oncogenic roles of JC polyomavirus in cancer

Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma

MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer

EZH2-Myc Hallmark in Oncovirus/Cytomegalovirus Infections and Cytomegalovirus' Resemblance to Oncoviruses

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

Ribosomal Protein S14 Negatively Regulates c-Myc Activity

c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis

CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells

Polyomavirus ALTOs, but not MTs, downregulate viral early gene expression by activating the NF-κB pathway

PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells

Sal-like Protein 2 Upregulates P16 Expression Through a Proximal Promoter Element.

Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

Pp2a-B56 Alpha Controls Oncogene-Induced Senescence In Normal And Tumor Human Melanocytic Cells

Stabilization of the C-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

Global Mapping Of C-Myc Binding Sites And Target Gene Networks In Human B Cells

HMG-I/Y, a New C-Myc Target Gene and Potential Oncogene